VNA
LYRA

Valley National Advisers’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Valley National Advisers’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$4K – 872
2025
Q2 		$4K Buy
+500
New +$4.15K ﹤0.01% 668

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Valley National Advisers's LYRA Position: Q3 2025 in Review

Valley National Advisers sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2025, closing a stake of 500 shares — an estimated $4K sold.

Valley National Advisers first reported a position in LYRA in Q2 2025 and held it in 1 quarter. The position peaked at $4K in Q2 2025. 26 funds tracked by Wall St. Rank hold LYRA as of Q3 2025.

  • Valley National Advisers reported no remaining LYRA THERAPEUTICS INC position as of Q3 2025 after selling out during the quarter.
  • Valley National Advisers sold 500 LYRA THERAPEUTICS INC shares in Q3 2025, an estimated $4K.
  • Valley National Advisers first reported a position in LYRA THERAPEUTICS INC in Q2 2025 and held it in 1 quarter.
  • Valley National Advisers's LYRA THERAPEUTICS INC position peaked at $4K in Q2 2025.
  • 26 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2025.

Based on Valley National Advisers's 13F filing for Q3 2025, filed 17 Oct 2025.